Gemifloxacin is a fluoroquinolone antibiotic that is effective against C. pneumoniae and M. tuberculosis (MIC50s = 0.25 and 8 ?g/ml, respectively).1,2 Quinolones, including gemifloxacin, inhibit bacterial DNA gyrase and other topoisomerases.3,4 Formulations containing gemifloxacin are useful against respiratory tract infections, particularly community-acquired pneumonia and tuberculosis.1,5,6
1.Hammerschlag, M.R., Roblin, P.M., and Bébéar, C.M.Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogensJ. Antimicrob. Chemother.48(Topic T1)25-31(2001) 2.Ruiz-Serrano, M.J., Alcalá, L., Martínez, L., et al.In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugsAntimicrob. Agents Chemother.44(9)2567-2568(2000) 3.Collin, F., Karkare, S., and Maxwell, A.Exploiting bacterial DNA gyrase as a drug target: Current state and perspectivesAppl. Microbiol. Biotechnol.92(3)479-497(2011) 4.Weigel, L.M., Anderson, G.J., and Tenover, F.C.DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilisAntimicrob. Agents Chemother.46(8)2582-2587(2002) 5.Grossman, R.F., Hsueh, P.-R., Gillespie, S.H., et al.Community-acquired pneumonia and tuberculosis: Differential diagnosis and the use of fluoroquinolonesInt. J. Infect. Dis.1814-21(2014) 6.Pranger, A.D., Alffenaar, J.W.C., and Aarnoutse, R.E.Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: A pharmacokinetic and pharmacodynamic approachCurr. Pharm. Des.17(27)29002-29930(2011)